Key takeaway: On July 24, 2026, Laurus Labs Limited hosted its Q1 FY27 earnings conference call, where management reported a 29% increase in revenue to INR 2,026 crores, driven by growth in the CDMO segment and affordable medicines. The CDMO business saw a 69% growth, with sales reaching INR 835 crores, attributed to late-stage clinical and commercial deliveries. The affordable medicines division also performed well, generating INR 1,156 crores in revenue, a 10% year-on-year increase. Management highlighted ongoing investments in capacity and technology to meet client demands, including a significant capex increase from INR 1,000 crores to INR 2,000 crores for FY27. The company maintained healthy gross margins of 62.7% and EBITDA margins of 31.8%. Management expressed confidence in sustaining growth and value creation through their transformation strategy and ongoing investments in complex modalities and technologies.

Key takeaway: The transcript of Laurus Labs Limited's Q4 FY26 earnings conference call, held on April 30, 2026, detailed the company's strong performance, with revenues reaching INR 6,813 crores, a 23% increase from the previous year. Management highlighted significant growth in the CDMO business, which accounted for over 30% of total revenues, and a robust performance in the Affordable Medicines division, which saw an 18% growth. The company reported healthy gross margins around 60% and an EBITDA margin of 26.8%. Management discussed ongoing investments in capacity expansion, including a new greenfield project and advancements in peptide manufacturing. They expressed confidence in maintaining operational momentum despite potential geopolitical challenges affecting raw material availability. The call concluded with management emphasizing their commitment to strategic partnerships and continued investment in technology and capacity to support future growth.

Key takeaway: The investor presentation from Laurus Labs Limited, dated April 30, 2026, detailed the company's standalone and consolidated financial results for the fiscal year ending March 31, 2026. Laurus Labs reported revenues of ₹6,813 crore, reflecting a 23% increase year-over-year, driven by strong growth in both the Contract Development and Manufacturing Organization (CDMO) and Affordable Medicines divisions. The gross margin improved to 60.4%, and EBITDA rose by 64% to ₹1,826 crore, with a corresponding EBITDA margin of 26.8%. Net profits surged by 148% to ₹889 crore. The presentation highlighted ongoing investments in capacity expansion, including a ₹3,000 crore capex plan, and emphasized the company's commitment to sustainability and quality, with multiple regulatory certifications. Laurus Labs also reported a significant reduction in net debt to EBITDA ratio, indicating improved financial health.